There are no official guidelines to assist in answering this question. I will search for relevant research papers instead.
The FDA Drug Labels for semaglutide (PO), tirzepatide (PO) do not address this question.
From the Research
Equivalent Dosage of Semaglutide and Tirzepatide
The equivalent dosage of 14 mg semaglutide (Rybelsus) to tirzepatide (Mounjaro) is not directly stated in the provided studies. However, we can look at the efficacy and safety comparisons between the two medications:
- A study comparing tirzepatide to semaglutide found that tirzepatide at doses of 5 mg, 10 mg, and 15 mg was noninferior and superior to semaglutide 1 mg in reducing glycated hemoglobin levels in patients with type 2 diabetes 1.
- Another study found that oral semaglutide at doses of 7 mg and 14 mg was superior to sitagliptin in reducing HbA1c levels in patients with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea 2.
- A phase 1 clinical trial found that subcutaneous tirzepatide 15 mg was superior to semaglutide 1 mg in improving clamp disposition index, a measure of insulin secretion and sensitivity, in adults with type 2 diabetes 3.
Key Findings
- The studies suggest that tirzepatide may be more effective than semaglutide in reducing glycated hemoglobin levels and improving insulin sensitivity in patients with type 2 diabetes.
- However, the exact equivalent dosage of 14 mg semaglutide to tirzepatide is not established, as the studies used different doses and formulations of the medications.
- The available doses of oral semaglutide are 3 mg, 7 mg, and 14 mg, while tirzepatide is available in doses of 2.5 mg, 5 mg, and 10 mg 4.
Comparison of Efficacy and Safety
- The efficacy and safety of oral semaglutide and tirzepatide have been compared in several studies, with tirzepatide generally showing greater reductions in HbA1c levels and body weight.
- The safety profiles of the two medications are similar, with gastrointestinal adverse events being the most common 1, 3.